Augustus Loi

HealthBeacon is a medical adherence technology company. We develop smart tools for managing medication.

Medo.ai envisions the stethoscope of the future by bringing expert ultrasound diagnosis to your fingertips. At Medo, we augment ultrasound with artificial intelligence and cloud computing to bring expert-level on-the-spot diagnosis of ultrasound images to any clinician at point-of-care of a patient. This expertise can range from screening abnormalities in newborn babies at remote locations, monitoring old patients at home, aiding trauma patients in emergency rooms, to diagnosing liver and kidney diseases in family doctor's offices.

AI-enhanced Thyroid & Breast ultrasound reporting. See-Mode automatically analyzes ultrasound images, producing fast and accurate radiology reports. See-Mode automatically detects, sizes, and characterizes lesions according to ACR TI-RADS and BI-RADS, producing a complete sonographer worksheet and preliminary radiologist impressions.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

WEB offers the Spyder ECG platform, the worlds first direct patient to database ECG system that transcends huge distances, improving patient accessibility, data connectivity and physician reactivity for Cardiac Rhythm Management. The system is exponentially scalable with mainly a digital footprint, and clinically proven as an extended Holter ( up to 30 days continuously ) for diagnosis of infrequent, often asymptomatic but sometimes dangerous cardiac arrhythmias such as Paroxysmal atrial fibrillation, which increases the risk of stroke. The system can also be used for post discharge cardiac rhythm monitoring in high risk individuals including those post heart attacks, post cardiac surgery or post stroke individuals in the fully remote setting. The system has also been used for home based cardiac rehab and physiotherapy rhythm monitoring in at risk individuals. The data fluid system allows health care individuals to view immediately any streamed ECG data from a web-based interface on a tablet PC. Doctor Spyder also allows health care providers to generate a full report on the fly without the need of monitored individuals to physically return the Spyder device. The system is Medically CE marked and regulated and approved by HSA ( Health Sciences Authority ) of Singapore for remote ECG and Holter Monitoring indications. Spyder ECG database currently has greater than 11,000 individual sessions with a mean continuous average monitoring period of 4 days. The quality and quantity of Individual Data, and Population Data, make the Spyder ECG platform fully AI-Ready to be used for individual and population analysis for prediction of high risk arrhythmias in the near future. WEB is proud that the Spyder ECG improves #Patientaccessibility #Dataconnectivity and #Physicianreactivity.

NDR Medical Technology Pte. Ltd is the leading interventional robotics company. Our patented Automated Needle Targeting (ANT) technology facilitates accurate and precise needle punctures in the minimally invasive image-guided procedures for lung, liver, kidney, spine, etc. With our vision to lead AI-empowered interventional robotics, we strive to create revolutionary breakthroughs everyday.

TabSquare provides AI-powered 'smart' in-restaurant solutions to the F&B industry, leveraging rich consumer data and deep learning algorithms to provide an engaging dining experience for restaurants' diners and help increase restaurants' profitability. TabSquare's solutions currently collect over 30 million customer interaction data points on a monthly basis. With a unique data-driven approach to restaurant management and customer engagement, TabSquare helps partner restaurants drive higher sales, streamline operations, and provide a better customer experience. TabSquare is a market leader with operations in Singapore, Malaysia, Indonesia, Australia, Philippines, Taiwan, Hong Kong, Sweden, and UAE. Our clients include well-known F&B brands such as Burger King, KFC, Minor Food Group, Sushi Tei, Paradise Food Group, Japan Foods Holding, Zingrill Holdings, Strike Bowling, Old Town White Coffee, PappaRich, and many more.

Adatos.AI was founded in 2015, with the aim to be at the frontier of the digital revolution in agriculture and Nature-Based Solutions. Today, we operate globally from our offices in Singapore and the Netherlands to lead the way for more productivity, sustainable practices and the restoration of our planet’s ecosystems. Our mission is to provide accurate, actionable business insights by looking at the Earth’s skin. Using our leading AI and remote sensing technology to process vast amounts of data, we empower our clients to make better real-time decisions on the ground, every day.

Our Purpose Translating today’s emerging technologies into tomorrow’s opportunities Our Promise We catalyse innovation, accelerate growth and forge connections to build a thriving Deep Tech economy

Pacific Channel Climate Ventures | formerly ENGIE Factory Asia Pacific Pacific Channel Climate Ventures supports early-stage climate-tech companies developing technologies and business models that contribute to the energy transition. Previously operating as ENGIE Factory Asia Pacific, the platform is now managed by Pacific Channel Climate Ventures following its acquisition of ENGIE Factory Asia Pacific. Pacific Channel is a leading Australasian venture capital firm with more than 20 years’ experience investing in deep-tech ventures and supporting founders through the challenges of commercialisation and scale-up. Its approach is active and hands-on, with experience across climate-tech, health, agri-food and other complex technology sectors, and a focus on governance, investor engagement, strategic partnerships and long-term company building. The platform supports a portfolio of climate-tech ventures across Singapore and Southeast Asia, providing continuity for founders and management teams while connecting them with Pacific Channel’s broader investment platform across Australia, New Zealand, Singapore and the wider Asia-Pacific region. ENGIE remains connected through its wider global innovation ecosystem and will continue to provide corporate support to the ventures where relevant.

HealthBeacon is a medical adherence technology company. We develop smart tools for managing medication.

Medo.ai envisions the stethoscope of the future by bringing expert ultrasound diagnosis to your fingertips. At Medo, we augment ultrasound with artificial intelligence and cloud computing to bring expert-level on-the-spot diagnosis of ultrasound images to any clinician at point-of-care of a patient. This expertise can range from screening abnormalities in newborn babies at remote locations, monitoring old patients at home, aiding trauma patients in emergency rooms, to diagnosing liver and kidney diseases in family doctor's offices.

AI-enhanced Thyroid & Breast ultrasound reporting. See-Mode automatically analyzes ultrasound images, producing fast and accurate radiology reports. See-Mode automatically detects, sizes, and characterizes lesions according to ACR TI-RADS and BI-RADS, producing a complete sonographer worksheet and preliminary radiologist impressions.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.